Market closedADR
Takeda Pharmaceutical/$TAK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
$TAK
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Tokyo, Japan
Employees
49,281
Website
TAK Metrics
BasicAdvanced
$47B
17.31
$0.87
0.46
$0.51
3.56%
Price and volume
Market cap
$47B
Beta
0.46
52-week high
$15.22
52-week low
$12.58
Average daily volume
1.7M
Dividend rate
$0.51
Financial strength
Current ratio
1.313
Quick ratio
0.586
Long term debt to equity
71.381
Total debt to equity
73.206
Dividend payout ratio (TTM)
145.09%
Interest coverage (TTM)
6.57%
Management effectiveness
Return on assets (TTM)
2.51%
Return on equity (TTM)
2.94%
Valuation
Price to earnings (TTM)
17.311
Price to revenue (TTM)
0.77
Price to book
0.95
Price to tangible book (TTM)
-3.44
Price to free cash flow (TTM)
4.439
Dividend yield (TTM)
3.36%
Forward dividend yield
3.56%
Growth
Revenue change (TTM)
9.83%
Earnings per share change (TTM)
15.39%
3-year revenue growth (CAGR)
9.73%
3-year earnings per share growth (CAGR)
-22.36%
3-year dividend per share growth (CAGR)
2.17%
What the Analysts think about TAK
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
TAK Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TAK News
AllArticlesVideos
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
Seeking Alpha·22 hours ago
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Business Wire·2 weeks ago
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $47B as of March 14, 2025.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 17.31 as of March 14, 2025.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of March 14, 2025, the dividend rate is $0.50554 and the yield is 3.56%. Takeda Pharmaceutical has a payout ratio of 145.09% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.